Glasgow Prognostic Score (GPS)
Predicts overall survival in cancer patients based on C-reactive protein and albumin levels. A simple inflammatory-nutritional marker of cancer prognosis.
Score interpretation
Favourable inflammatory-nutritional status. Median survival varies by cancer type but favourable.
→ Optimise treatment; maintain nutritional support
Intermediate inflammatory-nutritional status
→ Nutritional intervention; consider impact on treatment decisions
Systemic inflammatory response with hypoalbuminaemia. Associated with significantly worse survival.
→ Palliative care discussion; aggressive nutritional and anti-inflammatory support
Interpretation bands for the Glasgow Prognostic Score. Apply clinical judgement and local guidance.
References
- McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540.
Related
Curated clinical cross-links plus same-class fallbacks.
- Fong Clinical Risk Score for CRC Liver Metastases · Cancer Prognosis
- FLIPI — Follicular Lymphoma International Prognostic Index · Cancer Prognosis
- CLL-IPI (International Prognostic Index for CLL) · Cancer Prognosis
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- WPSS — WHO Prognostic Scoring System for MDS · Cancer Prognosis
- Colchicine (Pericarditis / Post-MI Inflammation) · Pericarditis / Coronary Inflammation
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Dexamethasone · Corticosteroid — ENT Inflammation / Croup
- Vitamins with minerals and trace elements · Parenteral nutrition supplement
- Albumin solution · Plasma derivative / colloid
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.